Work

Supplementary Data from Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors

Year: 2023

Type: supplementary-materials

Abstract: Figure S1 shows the sequencing results for CRISPR/Cas9 gene editing to delete Brd4 in mouse MPNST cells; Figure S2 shows that BRD4 depletion overcomes resistance to BET inhibitor-induced cell death in MPNST; Figure S3 shows that genetic inhibition of BRD3 is sufficient to enhance MPNST cell sensitivity to JQ1; Figure S4 shows that JQ1 co-treatment with ARV771 does not markedly augment the apoptosis-initiation efficacy of ARV771 alone; Figure S5 shows that BET PROTAC ARV771 displays therapeutic efficacy in a human tumorigenic MPNST xenograft model.

DOI: 10.1158/1078-0432.22471128.v1

Authors: Jonathan M. Cooper, Amish J. Patel, Zhiguo Chen, Chung-Ping Liao, Kun Chen, Juan Mo, Yong Wang, Lu Q. Le

Institutions: The University of Texas Southwestern Medical Center, Harold C. Simmons Comprehensive Cancer Center

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361934437

Cites:

Cited by:

Related to: 10